An Introduction to Rheumatic Diseases
Rheumatic autoimmune diseases are debilitating, painful conditions that cause substantial morbidity and mortality. They constitute a wide spectrum of disorders, which can be due to an abnormal immune response in a specific area, such as rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, or can be systemic, such as systemic lupus erythematosus and systemic sclerosis (scleroderma). They are challenging to diagnose since they often present with nonspecific symptoms. The management of these conditions has been transformed in recent years with the development of biological disease-modifying anti-rheumatic drugs and targeted synthetic disease modifying drugs. However, many patients fail to achieve remission or develop side effects.
Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from the journal portfolio. This is complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Rheumatic Diseases Content
Clive Kelly, EULAR 2021: Nintedanib in RA-ILD – Findings from the INBUILD Trial
It was a pleasure to meet with Dr Clive Kelly (University of Newcastle-upon-Tyne, Newcastle, UK) to talk around his presentation on ‘Effects of nintedanib in patients with progressive fibrosing interstitial lung disease associated with rheumatoid arthritis (RA-ILD) in the INBUILD trial.‘ (OP0124), which was presented at the European Congress of Rheumatology 2021, 2-5 June 2021. […]
Rohit Aggarwal, ACR 2020 – Results of the ProDERM Study
We caught up with Rohit Aggarwal to discuss the efficacy and safety of IVIg (Octagam 10%) in patients with active dermatomyositis (Clinical Trial Identifier: NCT02728752). The abstract ‘Efficacy and Safety of IVIg (Octagam 10%) in Patients with Active Dermatomyositis. Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial (ProDERM Study)’ (ABSTRACT NUMBER: 0955) was presented […]
Maria Cinta Cid, ACR 2020 – Mavrilimumab in Patients with Giant Cell Arteritis (Part 2)
We had the pleasure to talk to Maria Cinta Cid (Hospital Clinic Barcelona, Barcelona, Spain) about the results of the phase 2 trial evaluating the use of mavrilimumab in patients with giant cell arteritis (Clinical Trial Identifier: NCT03827018). The abstract ‘Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody) Reduces Time to Flare and Increases Sustained Remission […]
Maria Cinta Cid, ACR 2020 – Mavrilimumab in Patients with Giant Cell Arteritis (Part 1)
We had the pleasure to talk to Maria Cinta Cid (Hospital Clinic Barcelona, Barcelona, Spain) about the use of mavrilimumab in patients with giant cell arteritis (Clinical Trial Identifier: NCT03827018). The abstract ‘Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody) Reduces Time to Flare and Increases Sustained Remission in a Phase 2 Trial of Patients with […]
Ihsane Hmamouchi, ACR 2020 – Clomipramine for Chronic Lumbar Radicular Pain
We were delighted to speak to Ihsane Hmamouchi regarding the use of clomipramine for the treatment of chronic lumbar radicular pain. The abstract ‘Efficacy of Clomipramine for Chronic Lumbar Radicular Pain a Randomized Clinical Trial’ (ABSTRACT NUMBER: 0962) was presented at the virtual ACR Convergence 2020, 5-9 November 2020. Questions What is the rationale for […]
Daniel Joe Lovell, ACR 2020 – Results from the Ongoing Phase IV PRCSG/PRINTO Registry
We caught up with Daniel Joe Lovell (University of Cincinnati School of Medicine, Cincinnati, OH, USA) to discuss the effectiveness of abatacept in juvenile idiopathic arthritis categories. The abstract ‘Response to Abatacept in JIA Categories: Results from the PRCSG/PRINTO JIA Abatacept Phase IV Registry’ (ABSTRACT NUMBER: 0714) was presented at the virtual ACR Convergence 2020, […]
Peter C Taylor, ACR 2020 – PT-CDAI as a Patient-Reported Clinical Disease Activity Index for use in Telemedicine (Part 3)
With COVID-19 forcing many rheumatologists to conduct consultations online, in Part 3 of our ACR 2020 highlights, Peter C Taylor (University of Oxford, Oxford, UK) summarises the investigation into the PT-CDAI, a patient-reported clinical disease activity tool that could help in target-based care in the era of telemedicine. The study entitled ‘Can a Clinical Disease […]
Letter from the Editor-in-Chief
touchREVIEWS in RMD. 2021;1:Online ahead of journal publication
Dear readers I am delighted to take on the mantle of Editor-in-Chief for touchREVIEWS in RMD and am grateful to have this opportunity to share some details of my background and my passion for great medical education with you. My first job after leaving school was to work (very briefly) for an estate agent in […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!